Clinical trial · Observational
Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer
NCT03455907CI-TRIAL-00110495BEVARTHRALGIA2completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arthralgia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients
- description
- patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
Primary outcomes (1)
- measure
- Frequency of arthralgia
- timeFrame
- At 6 months
- description
- Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.
Secondary outcomes (2)
- measure
- correlation between global cancer response and occurrence of arthralgia
- timeFrame
- baseline, at 3 months, at 6 months
- measure
- auto questionnaire specific to the study
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy * Male or female (aged ≥18 years old) * Performance Status (PS) between 0 and 2 * Expected life\> 3 months * Ability to answer a self-questionnaire * Obtaining the non-opposition of patient participation Exclusion Criteria: * Pregnant or lactating woman * Rapid evolution of neoplastic pathology * Major cognitive disorders that do not allow filling of the self-questionnaire * Impossibility to submit to medical monitoring for social, psychological or geographical reasons * Patients under guardianship or curatorship
References
Publications (1)
- RESULTVauleon E, Behal H, Lebellec L, Desbarbieux R, Baldacci S, Simon N, Pannier D, Vieillard MH, Turpin A. Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study. Cancer Chemother Pharmacol. 2021 Apr;87(4):533-541. doi: 10.1007/s00280-020-04226-6. Epub 2021 Jan 12. PMID 33438069